Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues |
| |
Authors: | María Angustias Muros Mariela Varsavsky Pablo Iglesias Rozas Javier Valdivia Juan Ramón Delgado Flavio Forrer Lisa Bodei Giovanni Paganelli |
| |
Institution: | (1) Nuclear Medicine Department and Oncology Department, Virgen de las Nieves University Hospital, Avda. Fuerzas Armadas, 2, ES-18014 Granada, Spain;(2) San Cecilio University Hospital, Granada, Spain;(3) Basel University Hospital, Basel, Switzerland;(4) European Oncology Institute, Milan, Italy |
| |
Abstract: | Objectives To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine
tumours (NET) after treatment with radiolabelled somatostatin analogues: 90Y-DOTAT-yr3-octreotide (90Y-DOTATOC) and 177Lu-DOTA-Tyr3- octreotate (177Lu-DOTATATE).
Material and methods The study included 5 patients with advanced NET referred to European centres for treatment with 90Y-DOTATOC and 177Lu-DOTATATE after lack of response to conventional treatment. The mean age was 45.6 years (29-68 years). Response to therapy
was assessed according to: (1) RECIST criteria, as complete response, partial response, stable disease or disease progression,
(2) post-treatment survival time and (3) quality of life, using the Karnofsky performance index.
Results All patients survived for >20 months after treatment; mean survival time was 28 months. At the time of writing, three of the
patients are alive after 20, 26 and 37 months. Partial response was observed in one patient, stable disease in three and disease
progression in the fifth patient. A good-to-excellent post-treatment quality of life was observed in all patients.
Conclusion Therapy with radiolabelled somatostatin analogues showed promising results in patients with advanced NET, with a partial response
or disease stabilisation in four of the five patients, who have enjoyed an extended survival period and an improved quality
of life. |
| |
Keywords: | Neuroendocrine tumours Radiolabelled somatostatin analogues 90Y-DOTATOC 177Lu-DOTATATE |
本文献已被 SpringerLink 等数据库收录! |
|